Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer.
This study evaluated surgical nodal management in women aged 70 years or older with early to locally advanced HR-/HER2+...
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
- Post category:Breast Cancer
- Reading time:1 min read
This study analyzed tumor-specific MHC-II (tsMHC-II) expression as a predictive biomarker in the phase III NeoTRIP trial...
Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss
- Post category:Breast Cancer/Digestive (CRC, Stomach) System/Genitourinary (Prostate, Bladder) System/Gynecologic Cancer/Melanoma/Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…
Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).
- Post category:Breast Cancer
- Reading time:1 min read
This multicenter phase II trial evaluated trastuzumab emtansine (T-DM1) in 36 patients with HER2-positive metastatic bre...
De-escalating axillary surgery in node-positive early breast cancer patients undergoing primary surgery: current evidence and recommendations.
- Post category:Breast Cancer
- Reading time:1 min read
This publication reviews the evolving management of the axilla in early breast cancer patients with low-volume biopsy-pr...
Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.
- Post category:Breast Cancer
- Reading time:1 min read
This study characterizes the cancer spectrum linked to the CHEK2 p.(Leu236Pro) variant in Mexican patients. Analyzing 5,...